Across TCGA pan-cancer cohorts, GOLGA8Q Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GOLGA8Q data layer compared with 18 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher GOLGA8Q Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA8Q expression acts as an unfavorable survival marker.
BRCA are the cancer types where GOLGA8Q Mutation most reproducibly stratifies survival.